NCT05022771View on ClinicalTrials.gov

A First in Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of PMG1015

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 14, 2021

Primary Completion Date

August 18, 2022

Study Completion Date

August 18, 2022

Conditions

Idiopathic Pulmonary Fibrosis

Interventions

DRUG

PMG1015 Dose 1

Dose level 1 of PMG1015

DRUG

PMG1015 Dose 2

Dose level 2 of PMG1015

DRUG

PMG1015 Dose 3

Dose level 3 of PMG1015

DRUG

PMG1015 Dose 4

Dose level 4 of PMG1015

DRUG

PMG1015 Dose 5

Dose level 5 of PMG1015

DRUG

PMG1015 Dose 6

Dose level 6 of PMG1015

DRUG

Placebo

Placebo to match

DRUG

PMG1015 Dose 7

Dose level 7 of PMG1015

Trial Locations (1)

4006

Q-Pharm Pty Ltd, Clive Berghofer Cancer Research Centre, Herston

All Listed Sponsors

lead

Pulmongene Ltd.

INDUSTRY

NCT05022771 - A First in Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of PMG1015 | Biotech Hunter | Biotech Hunter